CN104017837B - 瑞舒伐他汀中间体的酶法制备方法 - Google Patents
瑞舒伐他汀中间体的酶法制备方法 Download PDFInfo
- Publication number
- CN104017837B CN104017837B CN201410083458.8A CN201410083458A CN104017837B CN 104017837 B CN104017837 B CN 104017837B CN 201410083458 A CN201410083458 A CN 201410083458A CN 104017837 B CN104017837 B CN 104017837B
- Authority
- CN
- China
- Prior art keywords
- enzymatic
- rosuvastatin
- process preparation
- lipase
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 52
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title claims abstract description 46
- 229960000672 rosuvastatin Drugs 0.000 title claims abstract description 46
- 229920001661 Chitosan Polymers 0.000 claims abstract description 48
- 108090001060 Lipase Proteins 0.000 claims abstract description 30
- 239000004367 Lipase Substances 0.000 claims abstract description 30
- 102000004882 Lipase Human genes 0.000 claims abstract description 30
- 235000019421 lipase Nutrition 0.000 claims abstract description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 150000001412 amines Chemical class 0.000 claims abstract description 12
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- 239000000758 substrate Substances 0.000 claims abstract description 4
- 230000000694 effects Effects 0.000 claims abstract description 3
- 229940040461 lipase Drugs 0.000 claims description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 22
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000008346 aqueous phase Substances 0.000 claims description 9
- 238000007664 blowing Methods 0.000 claims description 9
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical group C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000012074 organic phase Substances 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- -1 polyoxyethylene Polymers 0.000 claims description 6
- 108010084311 Novozyme 435 Proteins 0.000 claims description 5
- 102000019280 Pancreatic lipases Human genes 0.000 claims description 4
- 108050006759 Pancreatic lipases Proteins 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229940116369 pancreatic lipase Drugs 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 238000002390 rotary evaporation Methods 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 239000000543 intermediate Substances 0.000 claims 11
- WBSFJYIYABHYRN-UHFFFAOYSA-N n-[5-(diethoxyphosphorylmethyl)-4-(4-fluorophenyl)-6-propan-2-ylpyrimidin-2-yl]-n-methylmethanesulfonamide Chemical class CCOP(=O)(OCC)CC1=C(C(C)C)N=C(N(C)S(C)(=O)=O)N=C1C1=CC=C(F)C=C1 WBSFJYIYABHYRN-UHFFFAOYSA-N 0.000 claims 11
- 229940045110 chitosan Drugs 0.000 claims 2
- 239000000047 product Substances 0.000 abstract description 28
- 108090000790 Enzymes Proteins 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 9
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 239000006227 byproduct Substances 0.000 abstract description 4
- 238000007086 side reaction Methods 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 20
- IBMRTYCHDPMBFN-UHFFFAOYSA-N Mono-Me ester-Pentanedioic acid Natural products COC(=O)CCCC(O)=O IBMRTYCHDPMBFN-UHFFFAOYSA-N 0.000 description 10
- 238000007098 aminolysis reaction Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000007867 post-reaction treatment Methods 0.000 description 2
- 238000007493 shaping process Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410083458.8A CN104017837B (zh) | 2014-03-07 | 2014-03-07 | 瑞舒伐他汀中间体的酶法制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410083458.8A CN104017837B (zh) | 2014-03-07 | 2014-03-07 | 瑞舒伐他汀中间体的酶法制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104017837A CN104017837A (zh) | 2014-09-03 |
CN104017837B true CN104017837B (zh) | 2015-08-12 |
Family
ID=51434833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410083458.8A Active CN104017837B (zh) | 2014-03-07 | 2014-03-07 | 瑞舒伐他汀中间体的酶法制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104017837B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106676141B (zh) * | 2015-11-06 | 2020-12-08 | 浙江京新药业股份有限公司 | 手性中间体(s)-3-羟基戊二酸单酯的酶法制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013080219A2 (en) * | 2011-11-28 | 2013-06-06 | Mylan Laboratories Ltd | NOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS |
-
2014
- 2014-03-07 CN CN201410083458.8A patent/CN104017837B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013080219A2 (en) * | 2011-11-28 | 2013-06-06 | Mylan Laboratories Ltd | NOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS |
Also Published As
Publication number | Publication date |
---|---|
CN104017837A (zh) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103497978B (zh) | 一种高光学纯l‑肉碱的制备方法 | |
CN104017837B (zh) | 瑞舒伐他汀中间体的酶法制备方法 | |
CN101974109B (zh) | 一种马来酰化半纤维素的制备方法 | |
CN103571890B (zh) | 一种用橄榄苦甙制备羟基酪醇的方法 | |
CN103304467A (zh) | 一步法制备n-咖啡酰色胺的方法 | |
CN110483317A (zh) | 高纯度3-异丁基戊二酸二甲酯的制备方法及应用 | |
CN104292201B (zh) | 3‑酯基儿茶素的制备方法 | |
CN104327034B (zh) | 5位和7位酯基儿茶素分子选择性制备方法 | |
CN110128385A (zh) | 一种通过十二酰氯化学修饰的槲皮素衍生物及其合成方法 | |
CN113024364A (zh) | 一种羟基香茅醛的高效绿色合成方法 | |
CN103865976B (zh) | 一种生物化学拆分8-苄基-7,9-二氧代-2,8-二氮杂双环[4.3.0]壬烷的方法 | |
CN107188816B (zh) | 一种改进的脂肪酸单乙醇酰胺的合成方法 | |
Ikai et al. | Synthesis of polysaccharide derivatives bearing bromobenzoate pendants for use as chiral auxiliaries | |
CN105622593A (zh) | 一种烟曲霉素的提取方法 | |
CN104610201B (zh) | 一种l‑抗坏血酸蓖麻酸酯及其制备方法与应用 | |
CN104292188A (zh) | 一种卡巴他赛的合成方法 | |
CN104447697A (zh) | 一种达比加群酯中间体的制备方法 | |
CN102233017B (zh) | 利用角质酶提取苹果多酚的方法及其应用 | |
CN106631709B (zh) | 一种羟基酪醇的提取及硝基化的方法 | |
CN102603538B (zh) | 一种n,2-烯丙基苯胺类化合物的制备方法 | |
CN101157694B (zh) | 咔啉化合物,其应用和其制备方法 | |
CN104311524B (zh) | 3’,4’,5,7-四酯基儿茶素的选择性制备方法及产品 | |
CN104829644B (zh) | 一种(s)‑叔丁基二甲基硅氧基‑戊二酸单苄酯单酰胺的制备方法 | |
CN102702127A (zh) | 一种n,5-二甲基-2-氨基噁唑的合成方法 | |
KR102037334B1 (ko) | 인-시츄 에스터 교환반응을 이용하여 미세조류로부터 바이오디젤을 제조하는 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: No. 800, East Xinchang Avenue, Yulin street, Xinchang County, Shaoxing City, Zhejiang Province 312500 Patentee after: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Country or region after: China Patentee after: Shaoxing Jingxin Pharmaceutical Co.,Ltd. Address before: No. 800, East Xinchang Avenue, Yulin street, Xinchang County, Shaoxing City, Zhejiang Province 312500 Patentee before: ZHEJIANG JINGXIN PHARMACEUTICAL Co.,Ltd. Country or region before: China Patentee before: SHANGYU JINGXIN PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |